Recent News

• 10.09.2026 - Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
• 10.06.2026 - Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
• 10.01.2026 - Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
• 09.11.2026 - Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
• 09.10.2026 - Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
• 08.27.2026 - Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
• 08.27.2026 - Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
• 08.14.2026 - Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
• 08.13.2026 - Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
• 08.12.2026 - Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Recent Filings

• 09.30.2026 - 8-K Current report
• 09.18.2026 - 8-K Current report
• 09.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 3 Initial statement of beneficial ownership of securities
• 08.27.2026 - 8-K Current report
• 08.19.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.18.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.17.2026 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 08.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership